Stambaugh J E, Drew J
Department of Pharmacology and Medicine, Jefferson Medical College and Cooper Hospital/University Medical Center, Philadelphia, Pa.
Clin Pharmacol Ther. 1988 Dec;44(6):665-9. doi: 10.1038/clpt.1988.209.
Thirty subjects with chronic moderate to severe pain who were receiving oxycodone/acetaminophen (oxy/APAP) for analgesia were initially evaluated for at least 7 days for oxy/APAP requirements for pain control. Each subject then received, in a randomized double-blind fashion, either 600 mg ibuprofen or placebo for an additional 7 days while hospitalized. Oxy/APAP usage was recorded daily along with efficacy and toxicity parameters. Overall global evaluations were also recorded on completion of the study. Comparison of mean differences before and after treatment with ibuprofen or placebo indicated a marked decrease in oxy/APAP use with ibuprofen (p less than 0.01) and a slight increase in use in the placebo group. Reduction in oxy/APAP usage occurred within 24 hours and maximized at 5 days. Overall global scores showed a marked preference for the ibuprofen combination over placebo (p less than 0.01). Daily pain intensity (p less than 0.05) and pain relief scores (p less than 0.05) also improved with the addition of ibuprofen. This study indicates that ibuprofen is efficacious in the management of chronic cancer pain, resulting in both enhanced analgesia and a reduction in concomitant narcotic use.
30名正在接受羟考酮/对乙酰氨基酚（oxy/APAP）镇痛治疗的慢性中重度疼痛患者，最初至少评估7天以确定控制疼痛所需的oxy/APAP剂量。然后，每位患者在住院期间以随机双盲方式额外接受7天的600毫克布洛芬或安慰剂治疗。每天记录oxy/APAP的使用情况以及疗效和毒性参数。研究结束时还记录了总体综合评估结果。布洛芬或安慰剂治疗前后平均差异的比较表明，布洛芬组oxy/APAP的使用量显著减少（p<0.01），而安慰剂组使用量略有增加。oxy/APAP使用量在24小时内开始减少，并在5天时达到最大降幅。总体综合评分显示，与安慰剂相比，布洛芬联合用药明显更受青睐（p<0.01）。添加布洛芬后，每日疼痛强度（p<0.05）和疼痛缓解评分（p<0.05）也有所改善。这项研究表明，布洛芬在慢性癌痛的治疗中有效，既能增强镇痛效果，又能减少同时使用的麻醉药品用量。
